Press Releases
CRYOPORT, INC. BEGINS PILOT SHIPPING PROGRAM FOR LEADING GLOBAL DIAGNOSTIC TESTING COMPANY
Shipments Will Be for an Upcoming Clinical Trial to be Conducted in Europe and USA
LAKE FOREST, CA – (MARKET WIRE) -- April 2, 2008 -- CryoPort, Inc. (OTCBB: CYRX.OB) today announced that it has begun a pilot shipping program for a leading global diagnostic testing company.
CryoPort will provide cold chain shipping services to support an upcoming clinical trial. The trial will involve CryoPort Express™ shipments in both the USA and Europe. This program will help the Company facilitate the establishment of the recycling infrastructure in Europe. Federal Express will handle all shipping segments.
Peter Berry, CEO of CryoPort, commented, “This pilot program is the start of our efforts to establish our product as a best in breed frozen shipping solution. These early shipments are going to ensure that our rollout of the CryoPort Express™ Shipper moves smoothly as we continue to learn and improve our processes.”
CryoPort has made numerous presentations to potential customers and continues to receive positive feedback with regard to the CryoPort Express™ Shipper.
Peter Berry continued, “Meeting the rigorous requirements of shipping samples for a multi-national clinical trial confirms the value of the CryoPort Express™ system for reducing the risk of losing critical patient data not only to the laboratory, but to the participating biopharma manufacturers and CROs. We welcome the opportunities to help pharmaceutical and biotechnology companies as well as CROs overcome their difficulties in shipping valuable clinical samples and products worldwide.”
To be added to CryoPort’s investor list, please email: edward@carpedminc.com
About CryoPort, Inc.
CryoPort (www.cryoport.com) develops leading edge, proprietary, technology-driven shipping and storage products for use in the rapidly growing global biotechnology and biopharmaceutical cold chain. The products developed by CryoPort are essential components of the infrastructure required for the testing, research and end user delivery of temperature-sensitive medicines and biomaterials in an increasingly complex logistical environment.
"SAFE HARBOR"
This press release contains forward-looking statements. The words "estimate," "possible" and "seeking" and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact: Stuart Fine
Carpe DM, Inc.
908-469-1788
stuart@carpedminc.com